Currently out of the existing stock ratings of Robert Hazlett, 82 are a BUY (88.17%), 10 are a HOLD (10.75%), 1 are a SELL (1.08%).

Robert Hazlett

Work Performance Price Targets & Ratings Chart

Analyst Robert Hazlett, carries an average stock price target met ratio of 37.96% that have a potential upside of 62.83% achieved within 352 days. Previously, Robert Hazlett worked at BTIG, LADENBURG.

Robert Hazlett’s has documented 163 price targets and ratings displayed on 27 stocks. The coverage was on Healthcare, Industrials, Technology, Consumer Cyclical, Energy sectors.

Most recent stock forecast was given on CMPS, Compass Pathways Plc at 24-Jun-2025.

Wall Street Analyst Robert Hazlett

Analyst best performing recommendations are on AXSM (AXSOME THERAPEUTICS).
The best stock recommendation documented was for AXSM (AXSOME THERAPEUTICS) at 12/17/2019. The price target of $97 was fulfilled within 3 days with a profit of $16.03 (19.8%) receiving and performance score of 65.99.

Average potential price target upside

of $316.08 (77.11%) on NKTR (NEKTAR THERAPEUTICS).
of $184.45 (78.53%) on EIGR (EIGER BIOPHARMACEUTICALS).
of $36.92 (124.49%) on ITCI (INTRACELLULAR TH).

ITCI Intracellular Th MNKD MannKind Corp PRTA Prothena plc RDHL Redhill Biopharma Ltd SEEL Seelos Therapeutics ZSAN Zosano Pharma Corp AXSM Axsome Therapeutics GRTX Galera Therapeutics NKTR Nektar Therapeutics EIGR Eiger Biopharmaceuticals FIXX Homology Medicines VSTM Verastem ARAV Aravive AKBA Akebia Ther AURA Aura Biosciences LYRA Lyra Therapeutics PRTK Paratek Pharmaceuticals CMPS Compass Pathways Plc RANI Rani Therapeutics Holdings SNDX Syndax Pharmaceuticals NXTC NextCure EIG Employers Holdings FIX Comfort Systems USA IT Gartner SEE Sealed Air AR Antero Resources Corp ZS Zscaler

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Charles Duncan (CANTOR FITZGERALD)